Study participants will be treated with long-pulsed 1064 nm Nd:YAG laser at the investigator's discretion based on the clinical endpoint (slight contraction and greying of the skin surface), the tumor characteristics, and the patient's skin phototype.

Thirty‐one subjects seeking treatment for biopsy‐proven BCC that did not meet the criteria for Mohs surgery were recruited. Subjects on current anticoagulation therapy, or with a history of immunosuppression were excluded. Subjects received one treatment with the 1064 nm Nd:YAG laser as follows: 5–6 mm spot, fluence of 125–140 J/cm2 and a pulse duration of 7–10 ms. Standard excision with 5 mm clinical margins was performed at 30 days after laser treatment to evaluate clinical and histologic clearance of BCC. Standardized photographs and adverse assessments were taken at the baseline visit, immediately after laser treatment and on the day of excision.
Nd:YAG laser: Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma

Yag Laser Treatment Of Basal Cell Carcinoma

Sex: Female, Male

Region of Enrollment

The primary outcome data collected during the study will include:
Number of tumors that showed histologic complete regression.

Study participants will be treated with long-pulsed 1064 nm Nd:YAG laser at the investigator’s discretion based on the clinical endpoint (slight contraction and greying of the skin surface), the tumor characteristics, and the patient’s skin phototype.
Nd:YAG laser: Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma

Single Arm

This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma.

11. The treatment area will be assessed post laser and at the final evaluation visit for purpura using the following scale:
0 = absence
1 = mild
2 = moderate
3 = severe

Subjects received one treatment with the 1064 nm Nd:YAG laser as follows: 5–6 mm spot, fluence of 125–140 J/cm2 and a pulse duration of 7–10 ms. Standard excision with 5 mm clinical margins was performed at 30 days after laser treatment to evaluate clinical and histologic clearance of BCC.

All Participants

• Clinical and Photographic Evidence of Extent of Purpura After Each Treatment

3. The treatment area will be assessed for edema using the following scale:
0 = absence
1 = mild
2 = moderate
3 = severe

Subjects received one treatment with the 1064 nm Nd:YAG laser as follows: 5–6 mm spot, fluence of 125–140 J/cm2 and a pulse duration of 7–10 ms. Standard excision with 5 mm clinical margins was performed at 30 days after laser treatment to evaluate clinical and histologic clearance of BCC.
30 to 90 days after laser treatment, all subjects are required to return for excision of the tumor site as located and recorded at the time of the first treatment. At this final follow-up visit, there is no will be no laser treatment. The following procedures and assessments will be performed.
The lesional areas to be treated will be located. A record of the size of the lesional area will be made.
The lesional area will be photographed.
The treatment area will be assessed for purpura, edema, erythema, scar or blistering using the following scale:
0 = absence
1 = mild
2 = moderate
3 = severe

• Clinical and Photographic Evidence of Extent of Edema Occurring After Each Treatment

The treatment area will be assessed for erythema using the following scale:
0 = absence
1 = mild
2 = moderate
3 = severe

Clinical and Photographic Evidence of Extent of Erythema Occurring After Each Treatment

The treatment area will be assessed for blistering using the following scale:
0 = absence
1 = mild
2 = moderate
3 = severe

Clinical and Photographic Evidence of Extent of Blistering Occurring After Each Treatment

Overall Study

Dr. Arisa Ortiz

Single arm/group study
Study participants will be treated with a long-pulsed 1064 nm Nd:YAG laser with a 5-7 mm spot, an approximate fluence of 100-200 J/cm2 and a pulse duration of 3-15ms determined somewhat at the investigator’s discretion based on the clinical endpoint (slight contraction and greying of the skin surface), the tumor characteristics, and the patient’s skin phototype. There will be no randomization.

Basal Cell Carcinoma

Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma

Nd:YAG laser

University of California San Diego

Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma

Arisa Ortiz

Director, Laser and Cosmetic Dermatology

University of California, San Diego

Massachusetts General Hospital

Eczema

DEC033 Study Product

DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study

Subjects completed the Visual Analog Scale for eczema symptoms - itching, scaling, and redness.

Dermatologic assessments for severity and size of lesions and Severity Scoring of Atopic Dermatitis (SCORAD) were assessed by a practitioner in the clinic.

sunburn/otok

Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma

DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study

Најкомплетнија база лековитог биља подржана науком